<DOC>
	<DOCNO>NCT02619097</DOCNO>
	<brief_summary>The primary objective trial ass safety pharmacokinetics profile pegolsihematide treatment anemia patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Safety &amp; Pharmacokinetics Pegolsihematide Treatment Anemia Patient With Myelodysplastic Syndromes</brief_title>
	<detailed_description>The study start low dose , 0.08mg/kg , group enroll 4 6 subject .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Men woman ≥18 year , premenopausal woman must negative pregnancy test . 2 . Documented diagnosis myelodysplastic syndrome ( MDS ) accord World Health Organization ( WHO ) criterion , include refractory anemia ( RA ) , refractory anemia ring sideroblast ( RARS ) , refractory cytopenia multilineage dysplasia ( RCMD ) , MDSU , 5q . 3 . Meets International Prognostic Scoring System ( IPSS ) classification low intermediate1 risk disease determine microscopic standard cytogenetic analysis bone marrow screen . 4 . Never erythropoietin agent treatment prior enrollment . 5 . Eastern cooperative oncology group ( ECOG ) performance status 0 1 screening . 6 . Hemoglobin ≥7g/dL ≤10g/dL , least two detection screen . 7 . Adequate transferrin saturation ( ≥15 % ) , ferritin ( ≥12ng/mL ) , folate ( ≥ low limit normal ) , vitamin B12 ( ≥ low limit normal ) 8 . Patients understand able provide write informed consent . 1 . Pregnant breast feed woman woman positive pregnant test , woman men whose spouse plan become pregnant 4 week end treatment . 2 . Therapyrelated secondary MDS . 3 . Previously diagnose intermediate2 high risk MDS per International Prognostic Scoring System ( IPSS ) . 4 . History severe allergic anaphylactic reaction hypersensitivity erythropoiesisstimulating agent polyethylene glycol . 5 . History red blood cell blood transfusion 4 week prior enrollment . 6 . Known disease lead anemia ( include haemolytic disease digestive tract hemorrhage ) . 7 . Uncontrolled hypertension 2 week prior enrollment , define systolic blood pressure ≥160mmHg diastolic blood pressure ≥ 95mmHg . 8 . Clinically significant systemic infection uncontrolled chronic inflammatory disease ( ie , rheumatoid arthritis , inflammatory bowel disease ) determine investigator screening . 9 . Evidence bone marrow collagen fibrosis , biopsy argentaffin stain show reticular fiber ≥＋＋ . 10 . History deep venous thrombosis arterial embolism within 12 month prior enrollment . 11 . History cardiocerebrovascular event within 6 month prior enrollment , include local ischemia , embolism , cerebral hemorrhage , transient ischemic attack , myocardial ischemia arterial thrombosis . 12 . Any serious medical condition , lab abnormality psychiatric illness within 6 month prior enrollment . 13 . History malignancy curatively treat nonmelanoma skin situ carcinoma . 14 . Estimated survival time ＜ 6 month . 15 . Plan get major surgery lead massive bleeding study . 16 . Treatment investigational drug within 6 week prior enrollment , plan participate investigational drug study . 17 . Any condition specifically note , judgement investigator , would preclude patient participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>